Influenza A (H1N1) 2009 Monovalent Vaccine and Skyrizi
Determining the interaction of Influenza A (H1N1) 2009 Monovalent Vaccine and Skyrizi and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than 10 mg/day or 1 mg/kg/day of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids. MANAGEMENT: In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines should be consulted. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities agree that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease). References "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA. Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]): Cerner Multum, Inc. "Australian Product Information." O 0 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18 "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA. "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI. "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC. "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA. CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]): View all 10 references
Professional:MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than 10 mg/day or 1 mg/kg/day of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids.
MANAGEMENT: In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines should be consulted. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities agree that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).
- "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.
- "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
- Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):
- Cerner Multum, Inc. "Australian Product Information." O 0
- CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
- "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.
- "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.
- CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):
Generic Name: influenza virus vaccine, h1n1, inactivated
Brand name:
Synonyms: Influenza A Vaccine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Influenza A (H1N1) 2009 Monovalent Vaccine-Skyrizi (150 MG Dose)
- Influenza A (H1N1) 2009 Monovalent Vaccine-Skyrizi Injection
- Influenza A (H1N1) 2009 Monovalent Vaccine-Skyrizi topical
- Influenza A (H1N1) 2009 Monovalent Vaccine-Sleep Aid
- Influenza A (H1N1) 2009 Monovalent Vaccine-Sleep Aid Tablets
- Influenza A (H1N1) 2009 Monovalent Vaccine-Sleepinal
- Skyrizi-Influenza A H1N1 Intranasal
- Skyrizi-Influenza A Vaccine
- Skyrizi-Influenza A Virus Vaccine (H5N1)
- Skyrizi-Influenza a virus vaccine, h1n1, inactivated Intramuscular
- Skyrizi-Influenza H1N1 Vaccine
- Skyrizi-Influenza Vaccine Live Intranasal